Guselkumab is the first-in-class monoclonal antibody targeting IL-23 developed by Janssen. It was approved by the FDA in July 2017 for the treatment of adult patients with moderate to severe plaque psoriasis. On November 26, 2018, TREMFYA (guselkumab) was approved in Hong Kong for the treatment of adult patients with moderate to severe plaque psoriasis.